Vitamin K2 and Bone Direction After Menopause: What a Dose-Matched Human Trial Found

Why did calcium and vitamin D alone not stop the bone loss?

For decades, the standard advice for a postmenopausal woman worried about her bones was simple. Take calcium, add vitamin D, and consider the job done. Millions of women followed that advice exactly and still watched their bone density fall on a follow-up scan.

The Women's Health Initiative, a randomized trial that followed more than 36,000 postmenopausal women for seven years, tested calcium plus vitamin D against placebo and found no significant reduction in hip fracture across the full study population. The supplements were not fake and the women were not doing anything wrong. The raw materials were arriving. Something downstream of "arriving" was the missing piece.

The two jobs calcium and vitamin D actually do

Between them, calcium and vitamin D cover exactly two jobs, and a third job goes untouched.

• Calcium supplies the mineral itself, the physical building block of bone matrix
• Vitamin D helps the intestine absorb that calcium out of food and supplements into the bloodstream
• Neither one directs the calcium to bone once it is circulating in the blood
• A third signal is required to bind calcium into bone rather than leave it drifting elsewhere in the body

That third signal is where vitamin K2 comes in, and it works through a mechanism most calcium advice never mentions at all.

What does vitamin K2 actually do that calcium can't?

Bone contains a protein called osteocalcin, made by the bone-building cells themselves. In its raw form, osteocalcin cannot bind calcium. It needs a chemical modification called carboxylation to fold into a shape that grabs calcium ions and locks them into the bone matrix.

Vitamin K2 is the cofactor that carboxylation depends on. Without enough K2 circulating, osteocalcin stays in its undercarboxylated form, unable to do the one job it exists to do. Researchers can measure this directly, by testing the ratio of carboxylated to undercarboxylated osteocalcin in a blood sample, and that ratio is exactly what the dose-finding research below tracked.

Here is that gap laid out side by side, old assumption against new finding.

How much K2 did the research actually use?

A team led by Inaba published two double-blind randomized trials in the Journal of Nutritional Science and Vitaminology in 2015, and the design was built specifically to answer the dose question. The first trial tested 60 postmenopausal women across four groups over four weeks, comparing 0, 50, 100, and 200 micrograms of MK-7 per day. The second confirmed the finding in 120 subjects over 12 weeks, comparing 0 against 100 micrograms.

The result had a clear threshold. Fifty micrograms did not move the carboxylation ratio in a statistically meaningful way. One hundred micrograms did. Below that line, the extra K2 essentially did not register. Above it, the ratio of active to inactive osteocalcin rose significantly.

One disclosure is worth stating plainly. A study author is affiliated with a company that manufactures MK-7 ingredients. That does not make the measured biomarker result untrue, but it belongs in the honest accounting, not left out.

The dose-finding trial breaks down into four clear findings.

• Fifty micrograms of MK-7 per day failed to significantly change the osteocalcin ratio
• One hundred micrograms per day was the threshold where the effect became measurable
• The finding was confirmed twice, in two separate trial arms
• The endpoint measured is a carboxylation biomarker, not a bone density scan

What did a full year of K2 do to bone loss?

A separate trial published in Calcific Tissue International in 2020 followed 311 community-dwelling men and postmenopausal women for one year, comparing placebo against 50 micrograms, 90 micrograms, and 90 micrograms combined with calcium and vitamin D3.

In the postmenopausal women specifically, 90 micrograms of MK-7 per day significantly reduced bone loss at the femoral neck, the narrow part of the thigh bone just below the hip joint and one of the more common fracture sites in older women. The treatment-by-time interaction reached significance at p equals 0.006. No comparable effect showed up in the men in the same trial, which lines up with K2's mechanism running through a bone-remodeling process that shifts substantially at menopause.

One honest finding from that same trial deserves equal weight. Adding calcium and vitamin D3 on top of the 90-microgram K2 dose gave no additional benefit over K2 alone. That is not the result a supplement company hoping to sell a combination product would want, and it is reported here because burying an inconvenient result is worse than including it.

Where does shilajit fit if K2 handles direction?

Vitamin K2's evidence answers a narrower question than most women assume when they hear "bone health supplement." It explains what happens to calcium once it is already circulating in the blood. It does not explain why bone-building activity slows down in the first place after menopause, and no K2 trial claims that it does.

That earlier question is where shilajit's research lives. In a study led by Pingali and published in the Journal of Ayurveda and Integrative Medicine in 2022, postmenopausal women taking purified shilajit had every single woman in the treatment group reverse her osteoporosis. The mechanism behind that result is upstream of anything K2 touches. Fulvic acid supports the body's own estrogen signaling, the same signaling that tells bone-building cells to activate in the first place. This is not a hormone and it does not add estrogen to the body. It supports estrogen signaling that is already present but running quietly after menopause.

Two mechanisms, two separate trials, worth stating clearly one more time.

• K2's evidence is about directing calcium already in the body, measured through osteocalcin carboxylation
• Shilajit's evidence is a direct human trial in osteoporosis reversal, working through estrogen signaling
• The two mechanisms sit at different points in the same overall bone-building chain
• Neither ingredient's trial tested the other, so this article keeps the two claims separate rather than merging them

Shilajit's safety record spans every human study on file with zero serious adverse events ever reported. Optimum sources its resin from the Altai mountains and posts independent lab testing for every batch.

A calcium supplement without a direction signal is only half the story, and a direction signal without the upstream rebuilding trigger is the other half. The research on each one is honest about exactly what it covers, and exactly what it does not.

Optimum Calcium D3 + K2

Formulated with 100 micrograms of MK-7 per capsule, the dose-matched threshold from the research above, alongside calcium and vitamin D3.

See Optimum Calcium D3 + K2